20 March 2023
SHARE NOW
Cell Therapy
Gene Therapy
Logistics
Regulatory & Standards
Supply Chain
Viral/Non-Viral Vectors
Maggie Chen, Head of Manufacturing at AGC Biologics, explores the challenges within the cell and gene therapy landscape.
In this interview, Maggie initially considers challenges associated with the cost of goods and supply chain, before discussing how standardization will benefit viral vector development.
Maggie goes on to address analytics and bad data as rate limiting factors to the progression of the field, and how a combination of different approaches may be what’s needed to realize the future of cell and gene therapies, before explaining what we might have to look forward to from AGC Biologics.
This interview has been produced in partnership with AGC Biologics and was recorded at Advanced Therapies Week 2023.
 |
 |
More like this
Scalable, xeno-free expansion of mesenchymal stem cells in a fixed-bed bioreactor
This case study showcases the successful expansion of mesenchymal stem cells (MSCs) using Rooster Bio’s xeno-free MSC platform in Univercells Technologies’ scale-X fixed-bed bioreactor. The collaboration highlights seamless process transfer, rapid cell attachment, optimized harvesting with high viability (>96%), and robust scalability from R&D to GMP manufacturing. Key innovations include predictive bioprocess monitoring with Scalia Vision and cost-effective solutions for advanced therapy manufacturing.
19 February 2025
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
